Find your next paid study

Institut de Recherches Internationales ServierNCT05786924

~$10 – $7,500

Phase 1

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivoluma…

Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer

H. Lee Moffitt Cancer Center and Research InstituteNCT05681780

ALPCO Syphilis-T and Syphilis-NT CLIA Kits: Detection of Antibodies to Treponema Pallidum and Against Lipoidal Antigens in Human Serum and Plasma

This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA K…

Treponema PallidumTreponema Pallidum InfectionSyphilis Infection+4 more

American Laboratory Products CompanyNCT07089836

~$10 – $1,125

NSCLCNon Small Cell Lung Cancer

A Randomized, Open-label, Phase 2a Dose Optimization Study of TUB-040 (a NaPi2b Antibody-drug Conjugate) in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer

The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patie…

~$10 – $8,750

Tubulis GmbHNCT07806773

Resectable Lung Non-Small Cell Carcinoma

Proton Beam Radiation Therapy in Patients With Resected N2 Non-Small Cell Lung Cancer

This clinical trial tests proton beam radiation therapy in patients with non-small cell lung cancer who have undergone surgical resection and have lymph nodes …

Emory UniversityNCT06008730

Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial

The proposed study is a proof-of-concept Phase 2, double-blind, randomized placebo-controlled clinical trial evaluating the safety and efficacy of tezepelumab …

Peanut Allergy

National Institute of Allergy and Infectious Diseases (NIAID)NCT07015996

~$10 – $5,625

NSCLCNSCLC, Stage INSCLC Stage II+5 more

A Phase II Study of BIO 300 to Reduce the Toxicity of Thoracic Radiotherapy for Patients With Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease (BREATHE)

The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people wi…

Memorial Sloan Kettering Cancer CenterNCT07323732

Phase 3

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared t…

Epithelial Ovarian CancerOvarian CancerFallopian Tube Cancer+1 more

Upper Extremity Vascularized Composite Allotransplantation: A Prospective Interventional Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

The primary objective of this study is to evaluate the 5-year (60-month) allograft survival rate of upper extremity vascularized composite allotransplantation …

Functional RecoveryUpper Extremity Vascularized Composite Allotransplantation

Yale UniversityNCT07810790

Phase 1

A Phase 1/1b, Open-Label, First-in-Human Multicenter Study to Assess the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of Oral TT-10 (an Adenosine 2A Receptor Antagonist), and TT-4 Diacid (an Adenosine 2B Receptor Antagonist), as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have fail…

Renal Cell CancerCastrate Resistant Prostate CancerNon Small Cell Lung Cancer+1 more

Portage BiotechNCT04969315

~$10 – $8,750

Lung CancerNon-small Cell Lung CancerMetastatic Lung Cancer+4 more

Timing of Immunotherapy and Effective Administration (TIMED): Effects of Infusion Timing on Treatment Response in Solid Tumors

This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell dea…

UNC Lineberger Comprehensive Cancer CenterNCT07630168

Phase 1

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to che…

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer